Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

World's first device-based treatment for small abdominal aortic aneurysms based on revolutionary new treatment paradigm

Cel

The Angiolutions device is a first-of-its-kind device stopping the life-threatening progression of small abdominal aortic aneurysm (AAA) – a pathological dilation of the aorta.
Angiolutions’ award-winning & patent-protected solution leverages a fundamentally new understanding of AAA growth discovered by the founders at Stanford University. They showed that stiffness gradients between the compliant (healthy) aorta and the adjacent stiff (diseased) aneurysm serve as a motor for AAA growth.
Based on this principle & together with key physicians, we developed a minimally-invasive, non-active aortic implant (class III). The nitinol-based device is positioned adjacent to the aneurysm sack via simple, catheter-based implantation. It is specifically designed to focally increase aortic stiffness in the compliant AAA neck region, thereby reducing stiffness gradients towards the stiff AAA sack that drive aneurysm growth.Hereby we achieve a fast, low-risk, size-stabilizing treatment of small AAA.

Dziedzina nauki (EuroSciVoc)

Słowa kluczowe

Program(-y)

Temat(-y)

System finansowania

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Wyświetl wszystkie projekty finansowane w ramach tego programu finansowania

Zaproszenie do składania wniosków

(odnośnik otworzy się w nowym oknie) HORIZON-EIC-2023-ACCELERATOR-01

Wyświetl wszystkie projekty finansowane w ramach tego zaproszenia

Koordynator

ANGIOLUTIONS GMBH
Wkład UE netto
€ 2 499 999,00
Adres
VAHRENWALDER STR 269A
30179 HANNOVER
Niemcy
MŚP
Tak
Region
Niedersachsen Hannover Region Hannover
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Linki
Koszt całkowity
€ 3 999 673,50